GHRL and Anorexia: The aim of this trial is to investigate the effect of individually dose‐optimized (dose escalation) twice‐daily subcutaneous (s.c.)natural ghrelin on safety, toxicity, tolerability, nutritional intake, anorexia, eating‐related symptoms, muscle mass, and strength and physical function in advanced cancer patients.